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Background: Complex fractionated atrial electrogram (CFAE)-targeted catheter ablation (CFAE ablation)
requires a high rate of atrial ﬁbrillation (AF) termination to provide good outcomes. We determined the
optimal settings of CFAE software.
Methods: In our 430 consecutive patients, AF was terminated in 97 (234/242) and 79% (149/188) of
patients with paroxysmal and persistent AF, respectively, by CFAE ablation combined with (31%) or
without (69%) pulmonary vein isolation, occasionally with nifekalant infusion. We analyzed 109
consecutive patients who underwent CFAE ablation to determine the optimal settings for comparing
subjective versus objective decisions by the CFAE software on CARTO3. We compared three settings: the
default setting (0.05–0.15 mV, 50–120 ms) and two modiﬁed settings (#1: 0.05–0.30 mV, 40–70 ms, #2:
0.05–0.13 mV, 10–20 ms). We retrospectively analyzed 11,425 points during left atrial mapping before
ablation and 10,306 points that were subjectively detected and ablated as CFAE points. An interval
conﬁdence level Z6 denoted a site with CFAE.
Results: With the default setting, the accuracy, sensitivity, speciﬁcity, positive productive value, and
negative productive values were 67, 42, 77, 48, and 73%, respectively. With modiﬁed setting #1, the
values were 78, 55, 87, 74, and 77%, respectively, versus 64, 82, 60, 53, and 91%, respectively, for modiﬁed
setting #2.
Conclusion: These data suggest that setting #1 was generally superior to the default setting, whereas
setting #2 was optimal for excluding areas not requiring ablation. The optimal CFAE software setting was
a voltage of 0.05–0.30 mV and an interval parameter of 40–70 ms.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Catheter ablation is an effective approach for the management of
patients with atrial ﬁbrillation (AF) [1–7]. Pulmonary vein isolation
(PVI) is one of the most common strategies of AF ablation, but the
outcome of PVI alone for patients with persistent AF is poor [8–10].
Additional approaches such as linear ablation after PVI have been
reported to improve the outcome [11–15]. Nademanee et al. also
described an alternative approach for AF ablation that involved
identifying the target “substrate” sites via electroanatomical
mapping of complex fractionated atrial electrograms (CFAEs)
[7–16,17]. Although PVI was not required with this approach, AF
ablation guided by CFAEs resulted in a high rate of success in
maintaining sinus rhythm in patients with either paroxysmal or
persistent AF. However, the results of these studies were not
replicated by others [6,18,19]. Thus, the role of CFAE-targeted
catheter ablation (CFAE ablation) in treating patients with AF
remains controversial. Because one of our physicians was a fellow
at the Paciﬁc Rim Electrophysiology Research Institute, all ﬁve
physicians in our Institute similarly terminate AF with CFAE ablation
[20,21]. In our latest study of 430 consecutive patients, AF was
terminated by CFAE ablation with (n¼133) or without (n¼297) PVI
in 97 (234/242) and 79% (149/188) of patients with paroxysmal and
persistent AF, respectively, occasionally with nifekalant infusion
without cardioversion. Thus, the use of optimal CFAE software
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settings on the CARTO3 may help physicians detect CFAE areas.
Therefore, we determined the optimal setting of CFAE software on
the CARTO3 system.
2. Materials and methods
2.1. Study population and protocol
This study comprised 109 consecutive patients (22 females, 87
males; mean age of 59710 years), including 57 (52%) patients
with paroxysmal AF, 40 (37%) patients with persistent AF, and 12
(11%) patients with long-standing persistent AF with symptomatic
drug refractory AF, who successfully underwent CFAE ablation
combined with (n¼44) or without (n¼65) PVI between May 2011
and May 2012. Thirty-seven patients had histories of AF ablation.
The patient characteristics and procedure data are shown in
Tables 1 and 2, respectively.
All antiarrhythmic drugs were discontinued at least ﬁve half-lives
before ablation, excluding amiodarone, which was discontinued at
least 3 months before ablation. Warfarin was not discontinued, and all
patients provided written informed consent for the procedure. This
study protocol was approved by our institutional ethics committee
(Approval date: July 18, 2013, Approval number: 355). AF was deﬁned
in accordance with the 2007 Heart Rhythm Society Expert Consensus
Statement [22]. Paroxysmal AF was deﬁned as recurrent AF (Z2
episodes) that terminates spontaneously within 7 days. Persistent AF
was deﬁned as AF that is sustained for 47 days or AF lasting o7 days
but necessitating pharmacologic or electrical cardioversion. AF lasting
41 year was deﬁned as longstanding persistent AF.
2.2. Mapping and ablation of AF
The AF ablation technique described by Nademanee et al. [7,16,17]
was used for this study, as previously reported [20,21,23,24]. In brief, a
3.5-mm NaviStar ThermoCool catheter (DF or FJ curve; Biosense
Webster, Diamond Bar, CA, USA) was used in all cases. After the
coronary sinus (CS) was cannulated via the femoral vein using a
decapolar catheter (Dynamic XT Decapolar Steerable-Cath; C. R. Bard,
Murray Hill, NJ, USA) for recording and induction, patients underwent
non-ﬂuoroscopic electroanatomical mapping with CARTO3 (Biosense
Webster). Heparin (3000 IU initial bolus, 1000–2000 IU subsequent
boluses as needed to maintain the activated clotting time 4300 s)
was administered for anticoagulation.
All electroanatomical maps were created for patients who dis-
played AF, either occurring spontaneously or by induction. Burst
pacing using a CS catheter to a lower limit of 1:1 capture or up to
150 ms was used to induce AF occasionally with a 0.01–0.02 μg/kg/
min isoproterenol infusion. AF was inducible in all patients at the
beginning of the procedure. When AF was terminated during
ablation procedure in patients with paroxysmal AF, AF was re-
induced until it was no longer inducible, as paroxysmal AF could
be terminated spontaneously. Electroanatomical maps were created
and displayed as a shortest complex interval (SCI) map, and the areas
of CFAE were also identiﬁed manually, tagged, and associated with
the atrial anatomy created by CARTO3. This enabled the operators to
associate areas of CFAE with the left atrium (LA), CS, and occasionally
the right atrium, thereby identifying target sites for ablation.
Bipolar recordings were ﬁltered at 30–500 Hz, and the CFAEs
were deﬁned as follows: (1) fractionated electrograms composed of
two or more deﬂections and/or a perturbation of the baseline with
continuous deﬂection of a prolonged activation complex; and (2)
atrial electrograms with an extremely short cycle length (r120 ms).
Examples of two intracardiac electrocardiograms displaying CFAEs
and normal atrial electrograms are shown in Fig. 1. Typical contin-
uous CFAEs before radiofrequency (RF) applications are easy to
detect, but the electrograms look different in each case and each
state of ablation. When AF is organized, CFAEs are also organized.
After a certain amount of RF applications, the amplitude and
frequency were decreased. This may be one of the reasons that CFAE
ablation has not been replicated easily by others [6]. We use CFAE
software but subjectively determine which electrograms are CFAEs.
All of the operators in our institute replicate CFAE ablation. Then, we
tried to optimize the CFAE software to perform CFAE ablation
clinically in other institutes with our subjective decision. Then, the
CFAE sites in this study were deﬁned as those that we ablated. In
addition, we calculated what setting is most appropriate to match
our subjective decisions.
After acquiring the SCI map associated with CFAEs, we searched
the areas of CFAEs referring to the tagged points because CFAE
areas have temporal spatial stability. RF was delivered with a
maximal power of 40 W with irrigation rates of 30 mL/min (3.5-
mm NaviStar ThermoCool catheter; Biosense Webster). The power
was reduced to 15 W in the posterior LA close to the esophagus or
in the CS. The primary endpoints during RF ablation were either
complete elimination of CFAE areas or conversion of AF to sinus
rhythm occasionally with the injection of nifekalant (0.3 mg/kg
intravenously over 10 min, maximum twice), a Class III antiar-
rhythmic drug similar to ibutilide, which is not available in Japan.
If the atrial arrhythmias were not successfully terminated, then
internal cardioversion was performed. The endpoints of the
procedure were termination of AF in patients with persistent AF
Table 1
Patient characteristics.
Paroxysmal Persistent Longstanding
persistent
AF (n¼57) AF (n¼40) AF (n¼12)
Age (years) 59711 5879 6077
Male (%) 77 85 75
Body mass index (kg/m2) 24.773.0 25.174.2 27.373.5
Hypertension (%) 56 53 67
Diabetes mellitus (%) 11 20 25
Heart failure (%) 14 25 25
HHD (%) 18 33 17
DCM (%) 4 8 0
HCM (%) 2 13 0
Ischemic heart disease (%) 7 8 0
Post cardiac operation (%) 4 3 0
Left atrial diameter (mm) 39.876.0 46.776.2 51.775.0
Left atrial volume (ml) 61.3719.9 82.7724.9 99.5729.9
LVEF (%) 65.0712.1 59.4713.1 65.776.5
BNP (pg/ml) 98.67175.2 177.97129.2 113.5779.4
ANP (pg/ml) 120.27528.1 74.6743.9 57.0727.5
HHD, hypertensive heart disease; DCM, dilated cardiomyopathy; HCM, hyper-
trophic cardiomyopathy; LVEF, left ventricular ejection fraction; AF, atrial
ﬁbrillation.
Table 2
Procedure data.
Paroxysmal Persistent Longstanding
persistent
AF (n¼57) AF (n¼40) AF (n¼12)
CFAE ablation combined with PVI (%) 56 48 33
Procedure time (min) 222745 229746 257747
Radiofrequency duration (min) 85724 87720 114720
Fluoroscopic time (min) 16710 14710 1077
Mapping points before ablation 105730 109748 124727
Mapping duration (min) 572 672 571
Use of cardioversion (%) 5 10 33
Use of nifekalant (%) 49 70 92
Mapping site/time; needed site/time for creating an electroanatomical map.
AF, atrial ﬁbrillation; CFAE, complex fractionated atrial electrogram; PVI, pulmon-
ary vein isolation.
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and non-inducibility of AF in patients with paroxysmal AF. If many
CFAE areas were identiﬁed before the delivery of RF ablation and
AF was terminated and non-inducible after ablation in limited
areas, this was the endpoint. However, AF was inducible until
ablation in the majority of CFAE areas in the majority of patients.
We did not attempt to eliminate CFAE areas in sinus rhythm
because of difﬁculties in detecting these areas in sinus rhythm.
2.3. Evaluation of optimal setting
A pilot study was performed to determine the optimal setting in
some cases. In CFAE software on CARTO3, minimum and maximum
duration values were attempted for all combinations of the following
values: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, and
150ms. In addition, minimum and maximum threshold values were
attempted for all combinations of the following values: 0.01, 0.03, 0.05,
0.08, 0.10, 0.13, 0.15, 0.18, 0.20, 0.23, 0.25, 0.28, 0.30, 0.33, 0.35, 0.38,
and 0.40 mV. In pilot studies, we identiﬁed two possible settings (#1:
0.05–0.30 mV, 40–70ms, #2: 0.05–0.13 mV, 10–20ms). We then
compared the two modiﬁed settings to the default setting and
calculated the accuracy, sensitivity, speciﬁcity, positive productive
value, and negative productive value for each setting. An interval
conﬁdence level Z6 was considered to denote a site with CFAE.
3. Results
We retrospectively analyzed 11,425 points during left atrial
mapping before ablation and 10,306 points that were subjectively
detected and ablated as CFAE points on CARTO3. We compared the
default setting (default: 0.05–0.15 mV, 50–120 ms) and two modiﬁed
settings according to a pilot study (#1: 0.05–0.30 mV, 40–70 ms, #2:
Fig. 1. Examples of complex fractionated atrial electrograms. (a) Fractionated electrograms with a continuous prolonged activation complex over the septal areas. (b) Normal
atrial electrograms during atrial ﬁbrillation in the left atrial appendage in the same patient.
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0.05–0.13 mV, 10–20 ms). We calculated the accuracy, sensitivity,
speciﬁcity, positive productive value, and negative productive value
for each setting. For the default setting, the accuracy, sensitivity,
speciﬁcity, positive productive value, and negative productive value
were 67, 42, 77, 48, and 73%, respectively. For modiﬁed setting #1,
these values were 78, 55, 87, 74, and 77%, respectively, compared to
64, 82, 60, 53, and 91%, respectively, for modiﬁed setting #2 (Table 3).
A comparison of each setting with the duration of AF is presented in
Table 4, and a comparison between de novo and repeat sessions for
each setting is presented in Table 5. Two example cases are shown in
Figs. 2 and 3. These data suggested that setting #1 is the optimal
setting in general, whereas setting #2 was optimal for excluding
areas that do not require ablation.
4. Discussion
This is the ﬁrst study to evaluate the optimal settings for CFAE
software on CARTO3 using maps with high rates of AF termination
with subjective determination. We ﬁrst performed a pilot study to
identify the optimal setting. However, the CFAEs varied substantially
for each patient. For example, AF was organized particularly in repeat
cases, although CFAEs were also organized. Next, we identiﬁed two
optimal settings: settings #1 and #2. For setting #1, the accuracy,
sensitivity, and speciﬁcity were 78, 55, and 87%, respectively,
whereas the positive and negative predictive values were 74 and
77%, respectively. Our ablation points matched the CFAE areas on SCI
maps in setting #1. For setting #2, the sensitivity (82%) was higher
than that for setting #1, whereas the speciﬁcity (60%) was lower.
Setting #2 could more widely recognize the CFAE areas. As the
negative predictive value (91%) of setting #2 was higher than that of
setting #1, this allowed us to easily exclude the areas that did not
Table 3
Comparison of the settings.
Default setting Setting #1 Setting #2
Accuracy (%) 67 78 64
Sensitivity (%) 42 55 82
Speciﬁcity (%) 77 87 60
Positive productive value (%) 48 74 53
Negative productive value (%) 73 77 91
Table 4
Comparison of the settings with the duration of atrial ﬁbrillation Paroxysmal AF/
Persistent AF/Longstanding persistent AF.
Default setting Setting #1 Setting #2
Accuracy (%) 68/66/64 79/77/78 67/62/60
Sensitivity (%) 41/39/55 57/50/66 82/80/91
Speciﬁcity (%) 77/78/71 87/88/86 62/58/62
Positive productive value (%) 44/51/55 71/75/81 49/55/64
Negative productive value (%) 75/70/68 79/76/73 93/87/94
Table 5
Comparison between the de novo and redo sessions for each setting First session/
Repeat session.
Default Setting Setting #1 Setting #2
Accuracy (%) 63/75 77/82 62/68
Sensitivity (%) 41/43 61/42 88/70
Speciﬁcity (%) 74/82 85/93 55/73
Positive productive value (%) 51/42 75/70 57/45
Negative productive value (%) 68/83 75/83 91/91
Fig. 2. Example CARTO maps of a patient. The shortest complex interval (SCI) map with red areas indicates complex fractionated atrial electrograms (CFAEs), and that with
purple areas indicates normal atrial electrograms. In the default setting (a), the ablated points do not match the red areas. In setting #1 (b, SCI: 0.05–0.30 mV, 40–70 ms), the
abated points match the red areas compared with the default setting, especially in the areas of the anterior septal wall and the antrum of the left superior pulmonary vein.
In setting #2 (c, SCI: 0.05–0.13 mV, 10–20 ms), the ablated points match the red areas, although non-ablated areas are also red. Setting #2 overestimates the CFAE areas, but it
may helpful to identify the areas that do not require ablation.
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require ablation in setting #2. These data suggest that our two
optimal settings provide a more sensitive and speciﬁc detection of
CFAE areas, which may aid physicians in CFAE ablation procedures.
Nevertheless, it remains possible that there are better settings than
those we determined, as we compared all of the settings only for
some patients in the pilot study, but we did not compare all of the
settings for all patients owing to time constraints.
There are several types of electrograms that we consider CFAEs. In
the original study [7], two types of electrograms were mentioned as
CFAEs: 1) fractionated electrograms composed of two or more
deﬂections and/or a perturbation of the baseline with continuous
deﬂection of a prolonged activation complex; and 2) atrial electro-
grams with an extremely short cycle length (r120ms). The software
attempted to cover both types of electrograms, requiring a wider
interval setting. Most electrograms requiring ablation are continuous
and more fractionated, for which a shorter interval setting may be
better in general.
5. Limitation
The present study had several limitations. (1) CFAEs were
evaluated visually by each operator in this study; however, CFAEs
were not universally deﬁned among the physicians. (2) Limited
software settings were evaluated in this study, and it is possible
that there are better settings. (3) The study design is retrospective.
6. Conclusions
The optimal settings of CFAE software on CARTO3 systemwere a
voltage range of 0.05–0.30 mV and an interval range of 40–70 ms.
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